Skip to main content
Premium Trial:

Request an Annual Quote

Nanogen Mulls Sale or Closure of Microarray Business in Bid to Focus on Clinical Dx

NEW YORK (GenomeWeb News) - Nanogen said yesterday that it is looking for ways to exit its microarray business as part of a plan to achieve profitability and focus on its clinical diagnostics strategy.
The company said it has hired Credit Suisse to help evaluate its options, “which may include a sale, partnering, or closure of the array business.”
Nanogen said it expects to complete the evaluation of the array business, which includes its NanoChip instruments and related reagents and consumables, within sixty to ninety days.
The company expects that the sale or closure of the microarray business will decrease expenses and improve cash flow by at least $15 million per year.
Robert Saltmarsh, Nanogen’s CFO, said that if the company sells or closes the segment, "the restructured business will show revenue growth on a year over year basis."
Nanogen said it plans to continue to focus on the clinical diagnostic market, with an “emphasis on real-time molecular and rapid point of care products."
Howard Birndorf, Nanogen CEO, said in a statement that despite “positive“ customer reception for its microarray product line, “multiplex molecular testing remains an early-stage market with slower growth and lower testing volumes than we expected."
He added, "The cost and effort to develop the broad product menu needed to be successful while also working to develop the clinical market over the next several years are large efforts and are expenses that Nanogen can no longer afford on its own." 
The plan follows several recent moves Nanogen has taken to augment its working capital, including a $50 million shelf offering in May and a $20 million convertible debt registered offering in August.

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.